JenniferLin

Associate

Hong Kong + 852.2526.6895

Connect:

Share

Jennifer Lin has in-depth practice experience in intellectual property, life sciences, and regulatory compliance in the pan-Asia region. She has assisted in intellectual property prosecution, enforcement, and commercialization in China and Hong Kong S.A.R. and has advised on multiple IP-related transactions including M&A, licensing, joint ventures, and other types of deals for clients from various industries such as Greystar, Henderson, Junshi, Incyte, Moody's, Stonepeak, and Sumitomo Dainippon Pharma.

As a PRC qualified lawyer based in Hong Kong, Jennifer has advised leading pharmaceutical and medical device companies on China's regulatory and compliance regimes in a wide range of legal aspects, including clinical trials, market authorization, human genetic resources, and data exportation. In addition, she has assisted clients that have significant business operations and interests in China and Hong Kong in compliance and risk management of cybersecurity, privacy, and data protection. She also has managed domestic trademark portfolios of Fortune 500 companies and prosecuted Hong Kong standard patents for multiple global biotech and pharmaceutical companies.

Prior to joining to Jones Day in 2019, Jennifer worked for a large Chinese law firm and represented clients in trademark, copyright, and patent disputes in Chinese courts. A copyright and unfair competition case that Jennifer extensively worked on was ranked as one of China's "Top 10 Most Study-Worthy IP Adjudications in 2018" by the Shanghai Intellectual Property Academy, which a favorable decision was later affirmed by the Guangzhou IP Court in 2023.

Experience

  • Gaw Capital Partners acquires Florentia Village Guangzhou Outlet MallJones Day advised Gaw Capital Partners in connection with the acquisition by a fund under Gaw’s management, alongside additional coinvestment partners, of Florentia Village Guangzhou, a designer outlet mall in Guangdong, China.
  • Junshi Biosciences forms joint venture with Rxilient Biotech to develop and commercialize toripalimab in Southeast AsiaJones Day advised Junshi Biosciences in the formation of a joint venture company, Excellmab, with Rxilient Biotech to develop and commercialize toripalimab, an anti-PD-1 monoclonal antibody drug, in nine Southeast Asian countries.
  • Incyte grants rights to CMS for ruxolitnib cream in China and Southeast AsiaJones Day represented Incyte Corporation in its Collaboration and License Agreement with CMS Aesthetics Limited for the development and commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK inhibitor ruxolitinib, for the treatment of autoimmune and inflammatory dermatologic diseases in Greater China and certain countries in Southeast Asia. 
  • Stonepeak forms strategic logistics investment partnership with EqualbaseJones Day represented Stonepeak, a leading U.S.-based alternative investment firm specializing in infrastructure and real assets, in connection with the formation of a Pan-Asia logistics real estate platform in partnership with Equalbase, a development, project, and asset manager specializing in industrial real estate assets in Asia.
    • View All

    Speaking Engagements

    • October 7, 2021
      Protection of Trademarks and Intellectual Property in China

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.